Composition for the treatment of COVID-19 infection, and a method of treatment
Inventors
Han, Qinghong • Hoffman, Robert
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12023370-B2
Publication Date
2024-07-02
Expiration Date
Abstract
Oral composition and a method for the treatment of coronaviruses infections in humans and animals. The method includes the steps of administering orally a methionine cleaving-enzyme; administering orally or parentally a protease inhibitor; and orally administering pyridoxal-L-phosphate in a fluid.
Core Innovation
The invention relates to a method for treating coronavirus infection in an individual in need thereof by administering an orally administered methioninase enzyme composition and pyridoxal-L-phosphates. The method includes administering an effective amount of a composition comprising a methioninase enzyme and administering an effective amount of pyridoxal-L-phosphates in a fluid. The approach is directed to coronavirus infection and, in refinements, to COVID-19 infection.
The invention further includes administering a protease inhibitor upon administering the methioninase enzyme. The protease inhibitor is administered orally or parentally in the method, and the protease inhibitor is characterized as a protease inhibitor of serine-protease inhibitor and/or cysteine-protease inhibitor. The method provides for the combination relationship by coordinating the methioninase enzyme administration with subsequent protease inhibitor administration.
In particular embodiments, the methioninase enzyme is a recombinant L-methionine α-deamino-γ-mercaptomethane lyase, and the protease inhibitors include camostat mesylate and/or E-64d. The pyridoxal-L-phosphate is administered as an oral fluid comprising an effective amount, including a fluid that is a solution of pyridoxal-L-phosphate in drinking water. These coordinated oral (and optionally parentally administered) components are used together in a coronavirus treatment method.
Claims Coverage
The independent claims cover 2 related coronavirus treatment methods. Each independent claim is built around a core combination of oral methioninase enzyme, pyridoxal-L-phosphate in a fluid, and protease inhibitor administration (with differences in whether the protease inhibitor is separated or combined into the same oral composition, and whether protease inhibition is oral or optionally parentally administered).
Oral methioninase enzyme administration
Administering, orally, an effective amount of a composition comprising methioninase enzyme to treat coronavirus infection in an individual in need thereof.
Oral pyridoxal-L-phosphate in a fluid
Administering, orally, a fluid comprising an effective amount of pyridoxal-L-phosphates, where the fluid is administered as part of the treatment.
Protease inhibitor administration upon methioninase enzyme dosing
Upon administering the methioninase enzyme, administering, orally or parentally, an effective amount of protease inhibitor as part of the coronavirus treatment.
Oral methioninase and oral protease inhibitor composition
Administering, orally, an effective amount of a composition comprising methioninase enzyme and an oral protease inhibitor to treat coronavirus infection.
Two-step oral regimen of methioninase/inhibitor composition and pyridoxal-L-phosphate fluid
Administering, orally, a fluid comprising an effective amount of pyridoxal-L-phosphate after the oral administration of the methioninase enzyme plus oral protease inhibitor composition.
Across the independent claims, the coverage centers on coordinated administration of a methioninase enzyme (optionally specified as recombinant L-methionine α-deamino-γ-mercaptomethane lyase), pyridoxal-L-phosphates delivered as an oral fluid, and a protease inhibitor (serine- or cysteine-protease inhibitor, optionally specified as camostat mesylate and/or E-64d), with protease inhibitor administration occurring either separately after methionase dosing (including oral or parentally) or combined within the orally administered methionase composition.
Stated Advantages
Oral administration and self-administration are described as advantages of the strategy.
Scalable production is described as an advantage.
Documented Applications
Treatment of coronavirus infection in an individual in need thereof, including COVID-19 infection.
Interested in licensing this patent?